Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 18/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30660336 | 0.80 | TXNRD1 (0.49) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL27175931 | 0.80 | TXNRD1 (0.62) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL30660395 | 0.79 | TXNRD1 (0.51) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL19284509 | 0.79 | TXNRD1 (0.48) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL2033509 | 0.78 | ALDH1A1 (0.38) | TXNRD1MAPTMAPK1NPSR1HTT | |
| SCHEMBL14938586 | 0.78 | CTSB (0.47) | TXNRD1S1PR4MAPTMAPK1 | |
| SCHEMBL10740434 | 0.76 | TXNRD1 (0.58) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL1428159 | 0.76 | TXNRD1 (0.58) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL1848090 | 0.76 | TXNRD1 (0.58) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL29830024 | 0.76 | TXNRD1 (0.58) | TXNRD1S1PR4MAPTS1PR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776445-B1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-08-10 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2776445-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068458-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-05-16 | — | — | WO | disclosed |
| EP-2084147-B1 | HETEROCYCLIC FXR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-04-25 | — | — | EP | disclosed |
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-07-22 | — | — | US | disclosed |
| WO-2009149795-A2 | HETEROCYCLIC CYCLOPROPYL-SUBSTITUTED FXR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | WO | disclosed |
| EP-2128158-A1 | Heterocyclic cyclopropyl-substituted FXR binding compounds | Phenex Pharmaceuticals AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2084147-A1 | HETEROCYCLIC FXR BINDING COMPOUNDS | Phenex Pharmaceuticals AG (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-7250418-B2 | Compounds as CRF1 receptor antagonists | PFIZER INC (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250418-B2 | Compounds as CRF1 receptor antagonists | PFIZER INC (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250418-B2 | Compounds as CRF1 receptor antagonists | PFIZER INC (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1583531-B1 | HETEROARYL-SUBSTITUTED PYRROLO[2, 3- B]PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-03-22 | — | — | US | disclosed |
| EP-1625125-A1 | COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS | Pharmacia & Upjohn Company LLC (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1583531-A1 | HETEROARYL- SUBSTITUTED PYRROLO' 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050038040-A1 | Compounds as CRF1 receptor antagonists | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2004099201-A1 | COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004062665-A1 | HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | CRHR1, CRHR2, CRH | TXNRD1 2598/4885S1PR4 1233/4885MAPT 3698/4885 |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | TXNRD1 350/4885S1PR4 3527/4885MAPT 2357/4885 |
| US-20050038040-A1 | Compounds as CRF1 receptor antagonists | CRHR1, CRHR2, CRH | TXNRD1 1030/4885S1PR4 455/4885MAPT 3507/4885 |
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | NR1H4, NR1H2, NR1H3 | TXNRD1 853/4885S1PR4 474/4885MAPT 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.